Printer Friendly

Research and Markets: Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019. Toxoplasmosis Continues to Threaten the Pregnant and Immuno-compromised as Drug Pipeline Disappoints.

DUBLIN -- Research and Markets ( has announced the addition of GlobalData's new report "Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019" to their offering.

GlobalData, the industry analysis specialist, has released its new report, Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Toxoplasmosis Therapeutics market. The report identifies the key trends shaping and driving the global Toxoplasmosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Toxoplasmosis Therapeutics sector.

Executive Summary:

While the number of people suffering from parasitic disease toxoplasmosis is due to rocket in the next few years, current treatments are not stepping up to the challenge, according to a new report by healthcare experts GlobalData.

The new report states that parasite reemergence has resulted from global warming, urbanization and subsequent changes in livestock systems, while severe side effects, hypersensitivity and drug compliance issues in congenital cases are increasing patient dissatisfaction with current treatment methods.

In addition, no drug is currently able to eliminate latent or inactive stages of the parasite's life cycle should an epidemic hit a vulnerable population.

Toxoplasmosis is a parasitic disease spread through contact with animals and raw meat, and is thought to be carried by up to half of the world's human population. Infection can cause mild, flu-like symptoms, though many individuals experience no illness. However, weakened immune systems in AIDS patients and pregnant women can lead to serious illness, with rare fatalities occurring.

The treatment market comprises of several drugs often prescribed in combination depending on the severity of the infection and the form of toxoplasmosis.

Spiramycin is used in pregnant women infected with Toxoplasma gondii during their first trimester to prevent transmission to the foetus, but it has not been approved by US Food and Drug Administration (FDA). Adverse side effects and unestablished safety profiles for pregnant women demonstrate the need for developments in toxoplasmosis drug testing.

The lack of epidemiology studies and screening programs used to investigate toxoplasmosis implies that clinical understanding of the parasite could still be improved.

For companies looking to enter this market, GlobalData estimates that the global toxoplasmosis therapeutics market is expected to grow at a CAGR of 3.9% from 2011, to reach $1.55 billion by 2019.

Reasons to Buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Toxoplasmosis Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

For more information visit

Source: GlobalData
COPYRIGHT 2012 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 11, 2012
Previous Article:Women are primary breadwinners, whether they like it or not.
Next Article:School's in for Summer: School of Rock Regional Summer Camp Attendance Up as Fast Growing Company Offers Students Unique Alternative.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters